Specialties

A diabetes patient’s risk for chronic kidney disease or cardiovascular disease can be impacted by various factors, including ethnic background. 

Studies of empagliflozin and dapagliflozin have shown to reduce cardiovascular risk, indicating a class effect for heart failure patients.

Diabetes causes metabolic changes that promote oxidative stress within the heart, resulting in changes that can impede its electrical signaling. 

Can use of the sodium-glucose cotransporter 1 and sodium-glucose cotransporter 2 dual inhibitor in patients with type 1 diabetes preserve kidney function?

Two-thirds of youth with Down syndrome have a BMI percentile at or above 85, but is this a marker for prediabetes and dyslipidemia in this population?

Insulin resistance and weight gain are common with PCOS and impact multiple CVD risk factors.

A post hoc analysis of the DECLARE-TIMI 58 trial may provide a new compelling indication for dapagliflozin.

Initiating the right medications upon diabetes diagnosis can help mitigate heart attack risk. 

Diabetes management can be a major factor in renal transplant aftercare; can DPP-4 therapy help improve outcomes?

Patients with psoriatic arthritis may be more prone to develop type 2 diabetes than the general population.